High Accuracy of Multislices Computed Tomography (MSCT) for Para-Aortic Lymph Node Metastases from Gastric Cancer: A Prospective Single-Center Study

2011 ◽  
Vol 18 (8) ◽  
pp. 2265-2272 ◽  
Author(s):  
Daniele Marrelli ◽  
Maria Antonietta Mazzei ◽  
Corrado Pedrazzani ◽  
Marianna Di Martino ◽  
Carla Vindigni ◽  
...  
Head & Neck ◽  
2015 ◽  
Vol 38 (S1) ◽  
pp. E1033-E1040 ◽  
Author(s):  
Nicklas Juel Pedersen ◽  
David Hebbelstrup Jensen ◽  
Nora Hedbäck ◽  
Martin Frendø ◽  
Katalin Kiss ◽  
...  

2006 ◽  
Vol 14 (31) ◽  
pp. 3060
Author(s):  
Zhi-Qing Zhao ◽  
Ke-Guo Zheng ◽  
Jing-Xian Shen ◽  
Wei Wang ◽  
Zi-Ping Li ◽  
...  

2014 ◽  
Vol 74 (2) ◽  
pp. 433-434 ◽  
Author(s):  
Daniele Marrelli ◽  
Maria Antonietta Mazzei ◽  
Franco Roviello

2011 ◽  
Vol 19 (4) ◽  
pp. 1251-1256 ◽  
Author(s):  
Hee Man Kim ◽  
Hyun Ki Kim ◽  
Sang Kil Lee ◽  
Jae Hee Cho ◽  
Kyung Ho Pak ◽  
...  

2017 ◽  
Vol 50 (5) ◽  
pp. 364-371
Author(s):  
Takanori Jinno ◽  
Yasuhiro Kurumiya ◽  
Ei Sekoguchi ◽  
Satoshi Kobayashi ◽  
Kiyotaka Kawai ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Wei Xu ◽  
Wentao Liu ◽  
Lingquan Wang ◽  
Changyu He ◽  
Sheng Lu ◽  
...  

BackgroundFor gastric cancer (GC) with extensive lymph node metastasis (bulky N2 and/or para-aortic lymph node metastases), there is no standard therapy worldwide. In Japan, preoperative chemotherapy (PCT) followed by D2 gastrectomy plus para-aortic lymph node dissection (PAND) is considered the standard treatment for these patients. However, in China, the standard operation for GC patients with only bulky N2 metastases was D2 gastrectomy. Besides, after PCT, whether doing PAND improves survival or not is debatable for GC patients with para-aortic lymph node (PAN) metastases. Therefore, we conducted this study to investigate whether D2 lymphadenectomy alone is suitable for these patients after PCT.MethodsWe retrospectively collected data on patients from our electronic medical record system. GC patients with bulky N2 and/or PAN metastases who underwent D2 lymphadenectomy alone after PCT were enrolled. The survival outcomes and chemotherapy responses were analyzed and compared with the results of the JCOG0405 study.ResultsFrom May 2009 to December 2017, a total of 83 patients met all eligibility criteria and were enrolled. The median survival duration for all patients was 40.0 months. The 3-year and 5-year OS rates for all patients were 50.3% and 45.6%, respectively. For patients with only bulky N2 metastasis, the 3-year and 5-year OS rates were 77.1% and 71.6%, respectively, which were similar to the results of the JCOG0405 study (82.7% and 73.4%). For patients with only PAN metastases, the 3-year and 5-year OS rates were 50.0% and 50.0%, respectively, which seemed to be lower than those of the JCOG0405 study (64.3% and 57.1%). For patients with bulky N2 and PAN metastases, the 3-year and 5-year OS rates were 7.4% and 0.0%, respectively, which were lower than those of the JCOG0405 study (20.0% and 20.0%).ConclusionThe results of our study suggest that D2 lymphadenectomy alone is suitable for GC patients with only bulky N2 metastasis after PCT. However, D2 lymphadenectomy alone perhaps is not suitable for patients with bulky N2 and PAN metastases after PCT.


Sign in / Sign up

Export Citation Format

Share Document